This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurology  • Ophthalmological Disorders, Other  • Immunology  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Ophthalmol. 2003;121:1039-1040.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE INVESTMENT of the National Eye Institute in the Optic Neuritis Treatment Trial¹ continues to pay dividends. In this issue of the ARCHIVES, the Optic Neuritis Study Group² reports on the risk of developing multiple sclerosis (MS) after an attack of isolated optic neuritis. This issue is of great importance to patients and physicians and, as the authors acknowledge, has been addressed in prior studies, some of which yielded similar results. However, with its impressive number of subjects, high retention rate, prospective design, standardized procedures, and well-defined criteria, the Optic Neuritis Treatment Trial has produced results that will likely be influential.

The Optic Neuritis Study Group provides 10- to 13-year follow-up on a cohort of patients who had experienced an attack of acute optic neuritis unaccompanied by other clinical evidence of MS. Follow-up was available on 87% of the original 388 patients, a remarkable achievement in itself. The . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

High- and Low-Risk Profiles for the Development of Multiple Sclerosis Within 10 Years After Optic Neuritis: Experience of the Optic Neuritis Treatment Trial
Optic Neuritis Study Group*
Arch Ophthalmol. 2003;121(7):944-949.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Using a Drug Before the Risks and Benefits Are Known From a Phase 3 Clinical Trial: Thoughts on Compassion
Miller
Arch Ophthalmol 2006;124:1029-1031.
FULL TEXT